Individualising Antithrombotic Strategies for Established Coronary Artery Disease

Published: 07 March 2023

  • Views:

    Views Icon 5400
  • Likes:

    Heart Icon 7
  • episode_image
    2m 25s
    Part 1 Summary Marco Valgimigli
Average (ratings)
No ratings
Your rating


In this on-demand version of the live broadcast, Radcliffe Medical Education bring together an expert panel to address the importance of providing individualised antithrombotic treatment in Acute Coronary Syndrome (ACS) and Chronic Coronary Syndrome (CCS). 


Chaired by Prof Marco Valgimigli (Instituto Cardiocentro Ticino, Lugano, CH), the panel review the two patient cases presented in phase one of this programme, present impactful new trial data, and discuss practical solutions to common challenges experienced in real-world practice.


Further, the faculty review and summarise the new recommendations for antithrombotic treatment strategies in ACS and CCS patients with established coronary artery disease (CAD) made in the 2022 joint clinical consensus statement of the European Association of Percutaneous Coronary Intervention (EAPCI), Association for Acute Cardiovascular Care (ACVC) and European Association of Preventive Cardiology (EAPC).


Note, the live version of this broadcast was CME accredited; this on-demand version is not.

This programme is supported by an unrestricted educational grant from AstraZeneca.

Learning Objectives

  • Summarise current guidance for choosing antithrombotic therapy in established CAD
  • Describe current gaps in clinical evidence and what is missing from current guidance
  • Adopt an evidence-based approach for managing patients with ACS and CCS

Target Audience

  • General Cardiologists
  • Interventional Cardiologists
  • Nurses
  • HCPs

More from this programme

Part 1


Join Prof Valgimigli as he provides an overview and summary of the following broadcast in this short and concise video.

1 session
Summary Watch now

Part 2

Patient Cases Revisited

Join Prof Navarese and Prof Vranckx as they present the two clinical case studies on ACS and CCS to be examined in this programme. Additionally, the panel review audience poll results on the initial approach to these patients.

Part 3

Development of a Consensus for Antithrombotic Therapy in CAD

Here Prof Valgimigli discusses the rationale behind the development of the new consensus statements on ACS and CCS, presents key data that has driven the recommendations, and highlights the shift in antiplatelet paradigm the consensus brings.

Part 4

Antithrombotic Treatment Strategies in Patients With Established CAD: Results of Two Network Meta-Analyses

Prof Navarese presents the results of a companion network meta-analysis on antithrombotic strategies in established CAD, including a ranking of individual strategies to identify best-in-class agents for key primary and secondary endpoints.

Part 5

Clinical Consensus Statements on Patients With ACS

Prof Kunadian summarises the recommendations made in the new joint clinical consensus statement of the EAPCI, ACVC and EAPC on patients with ACS, covering short and long-term strategy for monotherapy and dual/triple antiplatelet therapy.

Part 6

Clinical Consensus Statements on Patients With CCS

Prof Vranckx summarises the recommendations made in the new joint clinical consensus statement of the EAPCI, ACVC and EAPC on patients with CCS, covering individualised antithrombotic approaches and examination of bleeding risk.

Part 7

Panel Discussion and Q&A

Chaired by Prof Valgimigli, the faculty join to discuss the key learning points of the broadcast, answer audience questions and provide their expert opinion on the exemplar case studies.

Faculty Biographies

Eliano Navarese

Eliano Navarese

Director, Interventional Cardiology and Cardiovascular Medicine Research

Prof Eliano Navarese is associate Professor and Director of Research at the Cardiovascular Institute, Nicolaus Copernicus University, Poland and adjunct professor at University of Alberta, Canada.

His expertise is in the fields of interventional cardiology, coronary artery disease, antithrombotics, lipid-lowering therapies, cardiovascular pharmacotherapy, clinical trials and evidence-based medicine.

View full profile